LYEL
Income statement / Annual
Last year (2023), Lyell Immunopharma, Inc.'s total revenue was $130,000.00,
a decrease of 99.85% from the previous year.
In 2023, Lyell Immunopharma, Inc.'s net income was -$234.63 M.
See Lyell Immunopharma, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$130,000.00
|
$84.68 M
|
$10.65 M
|
$7.76 M
|
$657,000.00
|
| Cost of Revenue |
$0.00 |
$16.47 M |
$14.54 M |
$7.48 M |
$0.00 |
| Gross Profit |
$130,000.00 |
$68.22 M |
-$3.89 M |
$281,000.00 |
$657,000.00 |
| Gross Profit Ratio |
1 |
0.81 |
-0.36 |
0.04 |
1 |
| Research and Development
Expenses |
$182.95 M
|
$159.19 M
|
$138.69 M
|
$182.24 M
|
$63.60 M
|
| General & Administrative
Expenses |
$66.98 M
|
$117.31 M
|
$89.06 M
|
$46.88 M
|
$39.15 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$66.98 M
|
$117.31 M
|
$89.06 M
|
$46.88 M
|
$39.15 M
|
| Other Expenses |
-$2.79 M |
$1.89 M |
-$2.32 M |
-$9.43 M |
-$35.41 M |
| Operating Expenses |
$247.14 M |
$276.50 M |
$225.43 M |
$219.69 M |
$102.75 M |
| Cost And Expenses |
$247.14 M |
$276.50 M |
$225.43 M |
$219.69 M |
$102.75 M |
| Interest Income |
$23.45 M |
$7.05 M |
$1.17 M |
$5.94 M |
$8.12 M |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$20.25 M
|
$16.47 M
|
$14.54 M
|
$7.48 M
|
$4.38 M
|
| EBITDA |
-$225.25 M
|
-$166.65 M
|
-$199.94 M
|
-$207.64 M
|
-$100.83 M
|
| EBITDA Ratio |
-1732.68 |
-1.95 |
-15.47 |
-26.77 |
-153.47 |
| Operating Income Ratio
|
-1888.45
|
-2.16
|
-20.17
|
-27.33
|
-155.39
|
| Total Other
Income/Expenses Net |
$10.87 M
|
$3.84 M
|
-$36.65 M
|
$7.47 M
|
-$27.29 M
|
| Income Before Tax |
-$234.63 M |
-$183.12 M |
-$250.22 M |
-$204.47 M |
-$129.38 M |
| Income Before Tax Ratio
|
-1804.86
|
-2.16
|
-23.49
|
-26.36
|
-196.92
|
| Income Tax Expense |
$0.00 |
-$178.36 M |
$35.28 M |
-$5.94 M |
-$8.12 M |
| Net Income |
-$234.63 M |
-$4.75 M |
-$285.50 M |
-$198.53 M |
-$121.26 M |
| Net Income Ratio |
-1804.86 |
-0.06 |
-26.81 |
-25.6 |
-184.56 |
| EPS |
-0.93 |
-0.0192 |
-1.18 |
-0.81 |
-0.49 |
| EPS Diluted |
-0.93 |
-0.0192 |
-1.18 |
-0.81 |
-0.49 |
| Weighted Average Shares
Out |
$250.98 M
|
$247.08 M
|
$242.74 M
|
$246.58 M
|
$246.58 M
|
| Weighted Average Shares
Out Diluted |
$250.98 M
|
$247.08 M
|
$242.74 M
|
$246.58 M
|
$246.58 M
|
| Link |
|
|
|
|
|
